Our trade advice tool can cross-verify current
analyst consensus on Corcept Therapeutics and to analyze the company potential to grow in the current economic cycle.
The firm dividends can provide a clue to the current value of the stock. The entity is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Corcept Therapeutics income statement, its balance sheet, and the statement of cash flows. Potential Corcept Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Corcept Therapeutics investors may use each financial statement separately, they are all related. The changes in Corcept Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Corcept Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Corcept Therapeutics
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Corcept Therapeutics performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Corcept Therapeutics shares is the value that is considered the true value of the share. If
the intrinsic value of Corcept is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Corcept Therapeutics. Please read more on our
fundamental analysis page.
How effective is Corcept Therapeutics in utilizing its assets?
Corcept Therapeutics Incorporated reports assets on its Balance Sheet. It represents the amount of Corcept resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Corcept Therapeutics aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Pharmaceuticals space. To get a better handle on how balance sheet or income statements item affect Corcept volatility, please check the breakdown of all its
fundamentals.
Are Corcept Therapeutics Earnings Expected to grow?
The
future earnings power of Corcept Therapeutics involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Corcept Therapeutics factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Corcept Therapeutics
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Corcept
expected earnings.
Corcept Therapeutics Gross Profit
Corcept Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Corcept Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Corcept Therapeutics Gross Profit growth over the last 10 years. Please check Corcept Therapeutics'
gross profit and other
fundamental indicators for more details.
A Deeper Perspective
Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Corcept Therapeutics is not uncomon. Institutional investor usually refers to an organization that invests money in Corcept Therapeutics on behalf of clients or other money managers. Buying and selling of large positions of Corcept Therapeutics stock by institutional investors can create supply and demand imbalances that result in sudden price moves of Corcept Therapeutics stock. Let's take a look at how the ownership of Corcept is distributed among investors.
Ownership Allocation
Corcept Therapeutics holds a total of one hundred sixteen million six hundred thirty thousand
outstanding shares. The majority of Corcept Therapeutics
outstanding shares are owned by
other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Corcept Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Corcept Therapeutics. Please pay attention to any change in the institutional holdings of Corcept Therapeutics as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
| Retail Investors19.21% | Insiders9.92% | Institutions70.87% |
| Retail Investors | 19.21 |
| Insiders | 9.92 |
| Institutions | 70.87 |
| 2018 | 2019 | 2020 | 2021 (projected) |
Receivables | 17.59 M | 19.93 M | 26.2 M | 28.27 M | Inventories | 4.73 M | 5.42 M | 4.91 M | 5.3 M |
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Corcept Therapeutics has an asset utilization ratio of 661.03 percent. This implies that the company is making $6.61 for each dollar of assets. An increasing asset utilization means that Corcept Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.
| Current Assets | 516.28 Million | 78.66 |
| Assets Non Current | 100.59 Million | 15.33 |
| Tax Assets | 39.44 Million | 6.01 |
Our perspective of the newest Corcept Therapeutics gain
The market risk adjusted performance is down to -0.35 as of today.
As of the 10th of December, Corcept Therapeutics shows the
risk adjusted performance of
(0.06), and Mean Deviation of 2.13. Corcept Therapeutics
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen
technical drivers for Corcept Therapeutics, which can be compared to its rivals. Please confirm
Corcept Therapeutics standard deviation,
value at risk, as well as the
relationship between the Value At Risk and
kurtosis to decide if Corcept Therapeutics is priced correctly, providing market reflects its regular price of 18.75 per share. Given that Corcept Therapeutics has
jensen alpha of
(0.30), we suggest you to validate Corcept Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.
Our Conclusion on Corcept Therapeutics
Whereas some other companies in the biotechnology industry are either recovering or due for a correction, Corcept may not be as strong as the others in terms of longer-term growth potentials. In closing, as of the 10th of December 2021, our analysis shows that Corcept Therapeutics follows the market closely. The firm is
undervalued and projects
average odds of distress for the next 2 years. Our present 90 days recommendation on the firm is
Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Corcept Therapeutics Incorporated. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com